Fundraising Fox
/People
Sign in

Caroline Haegeman

Investor

Associate at Delin Ventures

New York, New York, United States

Find your path to Caroline

30 people in our graph can introduce you to Caroline.

Sign up to see every warm intro you have to Caroline

  • Paths you didn't know you had: your email and LinkedIn already hold routes to Caroline. We find them
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes you can't see from your own inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

About

Caroline Haegeman is Co-Founder and Chief Operating Officer of Athernal Bio, a company developing immunotherapies targeting high-risk clonal hematopoiesis, a precursor to acute myeloid leukemia. She holds a PhD in Oncology from Imperial College London and previously worked at Boston Consulting Group advising pharmaceutical and biotech companies on R&D and clinical strategy, and as a biotech investor at Delin Ventures. At Athernal, her responsibilities include corporate and capital strategy, cross-functional execution of preclinical programs, and advisor engagement.

Contact· self-published, not guessed

Experience

  1. Athernal BioCo-Founder, Chief Operating Officer (COO)current2024 — presentCambridge, England, United Kingdom
  2. IMMvention Therapeutix, Inc.Board Observercurrent2023 — present
  3. Delin VenturesSenior Investment Associate2025London Area, United Kingdom
  4. Delin VenturesInvestment Associate2023 — 2024Greater London, England, United Kingdom
  5. Boston Consulting Group (BCG)Senior Associate2022 — 2023Greater London, England, United Kingdom
  6. Box42 DatesDirector and Co-Founder2020 — 2023Greater London, England, United Kingdom
  7. Panacea InnovationPortfolio Manager & Consultant2020
  8. Panacea InnovationProgramme Principal2019 — 2020
  9. Panacea InnovationProgramme Lead2019Greater Oxford Area

Skills & more

Microsoft PowerPointResearch SkillsTherapeuticsDealsDue DiligenceMarket ResearchBiotechnologyCommercial DevelopmentStrategisingVenture CapitalPortfolio ManagementInvestments
+12 moreOrganization SkillsMicrosoft ExcelTeamworkDrug DiscoveryClinical TrialsTechnical WritingBiochemistryEntrepreneurshipTeachingCancer BiologyScience CommunicationLeadership

Languages Dutch · English · French

  • Science and Technology Venture Capitalist Fellowship — Royal Academy of Engineering

From Caroline's professional profile.

Colleagues at Delin Ventures

Alan Barge
Venture Partner at Delin Ventures
Carol Lynch
Advisor at Delin Ventures
Christopher Spray
Advisor at Delin Ventures
Colin Sims
Partner at Delin Ventures
Igor Linshits
Founder at Delin Ventures
Jakub Czarnecki
Financial Controller at Delin Ventures
John Campbell
EIR at Delin Ventures
Jonathan Hay
Partner at Delin Ventures

Frequently asked questions

Who is Caroline Haegeman?
Caroline Haegeman is Co-Founder and Chief Operating Officer of Athernal Bio, a company developing immunotherapies targeting high-risk clonal hematopoiesis, a precursor to acute myeloid leukemia. She holds a PhD in Oncology from Imperial College London and previously worked at Boston Consulting Group advising pharmaceutical and biotech companies on R&D and clinical strategy, and as a biotech investor at Delin Ventures. At Athernal, her responsibilities include corporate and capital strategy, cross-functional execution of preclinical programs, and advisor engagement.
Where does Caroline Haegeman work?
Caroline Haegeman is Associate at Delin Ventures.
Where did Caroline Haegeman go to school?
Caroline Haegeman studied at Imperial College London (Doctor of Philosophy - PhD, Oncology and Cancer Biology); UCL (Master of Science (MSc), Drug Discovery and Development); Imperial College London (Bachelor of Science (B.Sc. Hons), Biochemistry).

Same school

Shared employers

Also worked at Athernal Bio1

Colin FreundPartner at Delin Ventures